{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:23:42Z","timestamp":1792815822076,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The RNA-binding protein FUS is commonly mutated in familial cases of amyotrophic lateral sclerosis (ALS-FUS), where it forms cytoplasmic inclusions. In addition, non-mutated FUS is a constituent component of protein inclusions in approximately 5\u201310% of cases of frontotemporal lobar degeneration (FTLD). Overexpression of wild-type human FUS is toxic to\n                    <jats:italic>Drosophila<\/jats:italic>\n                    neurons, preventing normal development and shortening lifespan in adults. In this study, we demonstrated that removal of the nuclear localisation sequence (NLS) of FUS, a common consequence of ALS-associated mutations, unexpectedly prevents toxicity in\n                    <jats:italic>Drosophila<\/jats:italic>\n                    models despite inducing FUS cytoplasmic mislocalisation. Using novel flies capable of expressing mGFP-tagged FUS, we found that FUS forms dynamic protein granules in\n                    <jats:italic>Drosophila<\/jats:italic>\n                    nuclei and does not form insoluble aggregates. FUS and other FET-family paralogues interact with the repetitive disordered C-terminal domain (CTD) of the large subunit of RNA polymerase II (Polr2A). Using flies that have variable CTD repeat lengths, we demonstrated that FUS genetically interacts with the Polr2A CTD to induce toxicity. Finally, we demonstrated that this association with Polr2A could be relevant to human disease, finding that inclusion-bearing neurons of individuals with FUS-positive FTLD, but not ALS-FUS, show cytoplasmic mislocalisation of POLR2A (the Polr2A human orthologue). Together, these results imply that FUS can have a nuclear mechanism of toxicity when overexpressed in animal models. This toxicity occurs via interaction with RNA polymerase II and aberrant interaction between FUS and POLR2A may be involved in the pathogenesis of FTLD.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08539-x","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:34:23Z","timestamp":1773509663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Human FUS is toxic via association with RNA polymerase II in Drosophila"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4783-6257","authenticated-orcid":false,"given":"Thomas G.","family":"Moens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3274-0559","authenticated-orcid":false,"given":"Luca","family":"Biasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Scheveneels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-2453","authenticated-orcid":false,"given":"Bradley N.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1790-7376","authenticated-orcid":false,"given":"Claire","family":"Troakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-2357","authenticated-orcid":false,"given":"Philip","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-6951","authenticated-orcid":false,"given":"Caroline","family":"Vance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0104-4067","authenticated-orcid":false,"given":"Ludo","family":"Van Den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"8539_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162\u201372.","journal-title":"N Engl J Med"},{"key":"8539_CR2","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27:1918\u201329.","journal-title":"Eur J Neurol"},{"key":"8539_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1212\/01.wnl.0000172911.39167.b6","volume":"65","author":"GM Ringholz","year":"2005","unstructured":"Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586\u201390.","journal-title":"Neurology"},{"key":"8539_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.","journal-title":"Nat Rev Dis Primers"},{"key":"8539_CR5","doi-asserted-by":"publisher","first-page":"f4827","DOI":"10.1136\/bmj.f4827","volume":"347","author":"JD Warren","year":"2013","unstructured":"Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ. 2013;347:f4827.","journal-title":"BMJ"},{"key":"8539_CR6","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1126\/science.1166066","volume":"323","author":"TJ Kwiatkowski","year":"2009","unstructured":"Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205\u20138.","journal-title":"Science"},{"key":"8539_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.1165942","volume":"323","author":"C Vance","year":"2009","unstructured":"Vance C, Rogelj B, Hortob\u00e1gyi T, De Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208\u201311.","journal-title":"Science"},{"key":"8539_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","volume":"88","author":"Z-Y Zou","year":"2017","unstructured":"Zou Z-Y, Zhou Z-R, Che C-H, Liu C-Y, He R-L, Huang H-P. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2017;88:540\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8539_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00401-011-0838-7","volume":"122","author":"IRA Mackenzie","year":"2011","unstructured":"Mackenzie IRA, Ansorge O, Strong M, Bilbao J, Zinman L, Ang L-C, et al. Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation. Acta Neuropathol. 2011;122:87\u201398.","journal-title":"Acta Neuropathol"},{"key":"8539_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S1474-4422(24)00517-9","volume":"24","author":"TG Moens","year":"2025","unstructured":"Moens TG, Da Cruz S, Neumann M, Shelkovnikova TA, Shneider NA, Van Den Bosch L. Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications. Lancet Neurol. 2025;24:166\u201378.","journal-title":"Lancet Neurol"},{"key":"8539_CR11","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1038\/emboj.2010.143","volume":"29","author":"D Dormann","year":"2010","unstructured":"Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29:2841\u201357.","journal-title":"EMBO J"},{"key":"8539_CR12","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/nar\/gkq1162","volume":"39","author":"Y Kino","year":"2011","unstructured":"Kino Y, Washizu C, Aquilanti E, Okuno M, Kurosawa M, Yamada M, et al. Intracellular localization and splicing regulation of FUS\/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations. Nucleic Acids Res. 2011;39:2781\u201398.","journal-title":"Nucleic Acids Res"},{"key":"8539_CR13","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1093\/hmg\/ddt117","volume":"22","author":"C Vance","year":"2013","unstructured":"Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, Kathe C, et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet. 2013;22:2676\u201388.","journal-title":"Hum Mol Genet"},{"key":"8539_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40478-015-0202-6","volume":"3","author":"Y Kino","year":"2015","unstructured":"Kino Y, Washizu C, Kurosawa M, Yamada M, Miyazaki H, Akagi T, et al. FUS\/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2015;3:24.","journal-title":"Acta Neuropathol Commun"},{"key":"8539_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10465","volume":"7","author":"A Sharma","year":"2016","unstructured":"Sharma A, Lyashchenko AK, Lu L, Nasrabady SE, Elmaleh M, Mendelsohn M, et al. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 2016;7:10465.","journal-title":"Nat Commun"},{"key":"8539_CR16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-biochem-060614-034325","volume":"84","author":"JC Schwartz","year":"2015","unstructured":"Schwartz JC, Cech TR, Parker RR. Biochemical properties and biological functions of FET proteins. Annu Rev Biochem. 2015;84:355\u201379.","journal-title":"Annu Rev Biochem"},{"key":"8539_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/jnc.13588","volume":"138","author":"IRA Mackenzie","year":"2016","unstructured":"Mackenzie IRA, Neumann M. Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem. 2016;138:54\u201370.","journal-title":"J Neurochem"},{"key":"8539_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41586-023-06801-2","volume":"625","author":"S Tetter","year":"2024","unstructured":"Tetter S, Arseni D, Murzin AG, Buhidma Y, Peak-Chew SY, Garringer HJ, et al. TAF15 amyloid filaments in frontotemporal lobar degeneration. Nature. 2024;625:345\u201351.","journal-title":"Nature"},{"key":"8539_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00401-010-0698-6","volume":"120","author":"H Urwin","year":"2010","unstructured":"Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 2010;120:33\u201341.","journal-title":"Acta Neuropathol"},{"key":"8539_CR20","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1093\/brain\/awr201","volume":"134","author":"M Neumann","year":"2011","unstructured":"Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, Ansorge O, et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain. 2011;134:2595\u2013609.","journal-title":"Brain"},{"key":"8539_CR21","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1093\/hmg\/ddr150","volume":"20","author":"NA Lanson","year":"2011","unstructured":"Lanson NA, Maltare A, King H, Smith R, Kim JH, Taylor JP, et al. A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum Mol Genet. 2011;20:2510\u201323.","journal-title":"Hum Mol Genet"},{"key":"8539_CR22","doi-asserted-by":"publisher","first-page":"1008.e1","DOI":"10.1016\/j.neurobiolaging.2011.10.008","volume":"33","author":"L Miguel","year":"2012","unstructured":"Miguel L, Avequin T, Delarue M, Feuillette S, Fr\u00e9bourg T, Campion D, et al. Accumulation of insoluble forms of FUS protein correlates with toxicity in Drosophila. Neurobiol Aging. 2012;33:1008.e1\u201315.","journal-title":"Neurobiol Aging"},{"key":"8539_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1326-7-10","volume":"7","author":"R Xia","year":"2012","unstructured":"Xia R, Liu Y, Yang L, Gal J, Zhu H, Jia J. Motor neuron apoptosis and neuromuscular junction perturbation are prominent features in a Drosophila model of Fus-mediated ALS. Mol Neurodegener. 2012;7:10.","journal-title":"Mol Neurodegener"},{"key":"8539_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.nbd.2014.11.003","volume":"74","author":"S J\u00e4ckel","year":"2015","unstructured":"J\u00e4ckel S, Summerer AK, Th\u00f6mmes CM, Pan X, Voigt A, Schulz JB, et al. Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila. Neurobiol Dis. 2015;74:76\u201388.","journal-title":"Neurobiol Dis"},{"key":"8539_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.celrep.2018.06.070","volume":"24","author":"E Bogaert","year":"2018","unstructured":"Bogaert E, Boeynaems S, Kato M, Guo L, Caulfield TR, Steyaert J, et al. Molecular dissection of FUS points at synergistic effect of low-complexity domains in toxicity. Cell Rep. 2018;24:529\u201337.e4.","journal-title":"Cell Rep"},{"key":"8539_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gene.10150","volume":"34","author":"JB Duffy","year":"2002","unstructured":"Duffy JB. GAL4 system in Drosophila: a fly geneticist\u2019s Swiss Army Knife. Genesis. 2002;34:1\u201315.","journal-title":"Genesis"},{"key":"8539_CR27","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1128\/MCB.20.10.3345-3354.2000","volume":"20","author":"L Yang","year":"2000","unstructured":"Yang L, Embree LJ, Hickstein DD. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol. 2000;20:3345\u201354.","journal-title":"Mol Cell Biol"},{"key":"8539_CR28","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1101\/gad.204602.112","volume":"26","author":"JC Schwartz","year":"2012","unstructured":"Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR. FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev. 2012;26:2690\u20135.","journal-title":"Genes Dev"},{"key":"8539_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.celrep.2013.11.017","volume":"5","author":"JC Schwartz","year":"2013","unstructured":"Schwartz JC, Wang X, Podell ER, Cech TR. RNA seeds higher-order assembly of FUS protein. Cell Rep. 2013;5:918\u201325.","journal-title":"Cell Rep"},{"key":"8539_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.cell.2013.10.033","volume":"155","author":"I Kwon","year":"2013","unstructured":"Kwon I, Kato M, Xiang S, Wu L, Theodoropoulos P, Mirzaei H, et al. Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell. 2013;155:1049\u201360.","journal-title":"Cell"},{"key":"8539_CR31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.molcel.2019.01.008","volume":"73","author":"F Lu","year":"2019","unstructured":"Lu F, Portz B, Gilmour DS. The C-terminal domain of RNA polymerase II is a multivalent targeting sequence that supports Drosophila development with only consensus heptads. Mol Cell. 2019;73:1232\u201342.e4.","journal-title":"Mol Cell"},{"key":"8539_CR32","doi-asserted-by":"publisher","first-page":"20881","DOI":"10.1073\/pnas.1109434108","volume":"108","author":"J Couthouis","year":"2011","unstructured":"Couthouis J, Hart MP, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci USA. 2011;108:20881\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8539_CR33","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1093\/hmg\/dds116","volume":"21","author":"J Couthouis","year":"2012","unstructured":"Couthouis J, Hart MP, Erion R, King OD, Diaz Z, Nakaya T, et al. Evaluating the role of the FUS\/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21:2899\u2013911.","journal-title":"Hum Mol Genet"},{"key":"8539_CR34","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1093\/hmg\/ddu094","volume":"23","author":"JB Machamer","year":"2014","unstructured":"Machamer JB, Collins SE, Lloyd TE. The ALS gene FUS regulates synaptic transmission at the Drosophila neuromuscular junction. Hum Mol Genet. 2014;23:3810\u201322.","journal-title":"Hum Mol Genet"},{"key":"8539_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-012-1043-z","volume":"125","author":"JC Mitchell","year":"2013","unstructured":"Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B, et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273\u201388.","journal-title":"Acta Neuropathol"},{"key":"8539_CR36","doi-asserted-by":"publisher","first-page":"E4769","DOI":"10.1073\/pnas.1406162111","volume":"111","author":"CF Sephton","year":"2014","unstructured":"Sephton CF, Tang AA, Kulkarni A, West J, Brooks M, Stubblefield JJ, et al. Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proc Natl Acad Sci USA. 2014;111:E4769\u201378.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8539_CR37","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.40811","volume":"8","author":"S-C Ling","year":"2019","unstructured":"Ling S-C, Dastidar SG, Tokunaga S, Ho WY, Lim K, Ilieva H, et al. Overriding FUS autoregulation in mice triggers gain-of-toxic dysfunctions in RNA metabolism and the autophagy-lysosome axis. Elife. 2019;8:e40811.","journal-title":"Elife"},{"key":"8539_CR38","doi-asserted-by":"publisher","first-page":"e1003895","DOI":"10.1371\/journal.pgen.1003895","volume":"9","author":"Y Zhou","year":"2013","unstructured":"Zhou Y, Liu S, Liu G, Ozt\u00fcrk A, Hicks GG. ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet. 2013;9:e1003895.","journal-title":"PLoS Genet"},{"key":"8539_CR39","doi-asserted-by":"publisher","first-page":"6889","DOI":"10.1093\/nar\/gkaa410","volume":"48","author":"J Humphrey","year":"2020","unstructured":"Humphrey J, Birsa N, Milioto C, McLaughlin M, Ule AM, Robaldo D, et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res. 2020;48:6889\u2013905.","journal-title":"Nucleic Acids Res"},{"key":"8539_CR40","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1093\/hmg\/ddt328","volume":"22","author":"M Sabatelli","year":"2013","unstructured":"Sabatelli M, Moncada A, Conte A, Lattante S, Marangi G, Luigetti M, et al. Mutations in the 3\u2019 untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:4748\u201355.","journal-title":"Hum Mol Genet"},{"key":"8539_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5335","volume":"5","author":"S Dini Modigliani","year":"2014","unstructured":"Dini Modigliani S, Morlando M, Errichelli L, Sabatelli M, Bozzoni I. An ALS-associated mutation in the FUS 3\u2019-UTR disrupts a microRNA-FUS regulatory circuitry. Nat Commun. 2014;5:4335.","journal-title":"Nat Commun"},{"key":"8539_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-019-0658-x","volume":"7","author":"H An","year":"2019","unstructured":"An H, Skelt L, Notaro A, Highley JR, Fox AH, La Bella V, et al. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol Commun. 2019;7:7.","journal-title":"Acta Neuropathol Commun"},{"key":"8539_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00401-019-01998-x","volume":"138","author":"L Marrone","year":"2019","unstructured":"Marrone L, Drexler HCA, Wang J, Tripathi P, Distler T, Heisterkamp P, et al. FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138:67\u201384.","journal-title":"Acta Neuropathol"},{"key":"8539_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00401-024-02689-y","volume":"147","author":"P Tziortzouda","year":"2024","unstructured":"Tziortzouda P, Steyaert J, Scheveneels W, Sicart A, Stoklund Dittlau K, Barbosa Correia AM, et al. PP2A and GSK3 act as modifiers of FUS-ALS by modulating mitochondrial transport. Acta Neuropathol. 2024;147:41.","journal-title":"Acta Neuropathol"},{"key":"8539_CR45","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1002\/j.1460-2075.1996.tb00882.x","volume":"15","author":"A Bertolotti","year":"1996","unstructured":"Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. hTAF(II)68, a novel RNA\/ssDNA-binding protein with homology to the pro-oncoproteins TLS\/FUS and EWS, is associated with both TFIID and RNA polymerase II. EMBO J. 1996;15:5022\u201331.","journal-title":"EMBO J"},{"key":"8539_CR46","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1101\/gad.200303.112","volume":"26","author":"J-P Hsin","year":"2012","unstructured":"Hsin J-P, Manley JL. The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev. 2012;26:2119\u201337.","journal-title":"Genes Dev"},{"key":"8539_CR47","doi-asserted-by":"publisher","first-page":"8456","DOI":"10.1021\/cr400071f","volume":"113","author":"D Eick","year":"2013","unstructured":"Eick D, Geyer M. The RNA polymerase II carboxy-terminal domain (CTD) code. Chem Rev. 2013;113:8456\u201390.","journal-title":"Chem Rev"},{"key":"8539_CR48","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1128\/MCB.18.3.1489","volume":"18","author":"A Bertolotti","year":"1998","unstructured":"Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol. 1998;18:1489\u201397.","journal-title":"Mol Cell Biol"},{"key":"8539_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.molcel.2015.09.006","volume":"60","author":"KA Burke","year":"2015","unstructured":"Burke KA, Janke AM, Rhine CL, Fawzi NL. Residue-by-Residue view of in vitro FUS granules that bind the C-terminal domain of RNA polymerase II. Mol Cell. 2015;60:231\u201341.","journal-title":"Mol Cell"},{"key":"8539_CR50","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41556-020-00578-6","volume":"22","author":"M-T Wei","year":"2020","unstructured":"Wei M-T, Chang Y-C, Shimobayashi SF, Shin Y, Strom AR, Brangwynne CP. Nucleated transcriptional condensates amplify gene expression. Nat Cell Biol. 2020;22:1187\u201396.","journal-title":"Nat Cell Biol"},{"key":"8539_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ajhg.2019.06.016","volume":"105","author":"HA Haijes","year":"2019","unstructured":"Haijes HA, Koster MJE, Rehmann H, Li D, Hakonarson H, Cappuccio G, et al. De Novo heterozygous POLR2A variants cause a neurodevelopmental syndrome with profound infantile-onset hypotonia. Am J Hum Genet. 2019;105:283\u2013301.","journal-title":"Am J Hum Genet"},{"key":"8539_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12098-4","volume":"12","author":"Y-L Tsai","year":"2022","unstructured":"Tsai Y-L, Mu YC, Manley JL. Nuclear RNA transcript levels modulate nucleocytoplasmic distribution of ALS\/FTD-associated protein FUS. Sci Rep. 2022;12:8180.","journal-title":"Sci Rep"},{"key":"8539_CR53","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.cell.2015.07.047","volume":"162","author":"A Patel","year":"2015","unstructured":"Patel A, Lee HO, Jawerth L, Maharana S, Jahnel M, Hein MY, et al. A liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell. 2015;162:1066\u201377.","journal-title":"Cell"},{"key":"8539_CR54","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1093\/hmg\/ddu152","volume":"23","author":"M Yamashita","year":"2014","unstructured":"Yamashita M, Nonaka T, Hirai S, Miwa A, Okado H, Arai T, et al. Distinct pathways leading to TDP-43-induced cellular dysfunctions. Hum Mol Genet. 2014;23:4345\u201356.","journal-title":"Hum Mol Genet"},{"key":"8539_CR55","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/jnen\/nlab040","volume":"80","author":"JR Dickson","year":"2021","unstructured":"Dickson JR, Yoon H, Frosch MP, Hyman BT. Cytoplasmic mislocalization of RNA polymerase II subunit RPB1 in Alzheimer's disease is linked to pathologic Tau. J Neuropathol Exp Neurol. 2021;80:530\u201340.","journal-title":"J Neuropathol Exp Neurol"},{"key":"8539_CR56","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.cell.2018.06.006","volume":"174","author":"J Wang","year":"2018","unstructured":"Wang J, Choi J-M, Holehouse AS, Lee HO, Zhang X, Jahnel M, et al. A molecular grammar governing the driving forces for phase separation of prion-like RNA binding proteins. Cell. 2018;174:688\u201399.e16.","journal-title":"Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08539-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08539-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:01:56Z","timestamp":1774987316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08539-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8539"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08539-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LVDB is the head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experiments were performed in accordance with the applicable local guidelines and regulations. Human tissue studies were carried out under the ethical approval of the tissue bank (NHS Research Ethics Committee reference 23\/WA\/0124). Informed consent was obtained from all subjects for autopsy, neuropathological assessment and research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"310"}}